血清CA125、CA199、CA153联合检测在卵巢肿瘤中的运用

Evaluation of Serum CA125、CA199 and CA153 Detection in Ovarian Tumors

目的探讨血清CA125、CA199、CA153联合检测在卵巢肿瘤中的应用价值。方法采用MEIA法检测190例卵巢肿瘤患者(其中恶性肿瘤42例,良性包块148例)手术前血清CA125、CA199、CA153值,并对部分恶性肿瘤患者术后进行连续动态监测、随访。结果恶性肿瘤组血清CA125、CA199、CA153值均明显高于良性包块组(P<0.05)。CA125、CA199、CA153检测的敏感性、特异性分别为83.3%、71.6%;52.4%、86.0%;12.5%、97.9%。三者联合检测对卵巢恶性肿瘤的敏感性高达97.6%。恶性肿瘤患者术后连续监测CA125、CA199、CA153值显示三者血清水平高低与预后有关。结论CA125、CA199、CA153联合检测可提高卵巢肿瘤的诊断敏感性,同时对术后病情监测也有意义。

Objective To investigate the clinical value of serum CA125,CA199 and CA153 levels. Methods Preoperative serum CA125,CA199 and CA153 levels were evaluated in 190 patients with ovarian tumors by microparticle enzyme-immumoassay（MEIA）. The follow-up clinical response was also investigated. Results The mean value of CA125,CA199 and CA153 in malignant ovarian tumors was higher than that in benign tumors（P〈0.05）. The sensitivity and specificity of CA125 detection in ovarian carcinoma were 83.3% and 71.6%, those of CA199 were＇52. 4% and 86.0%, and sensitivity of combined CA153 ,CA199 and CA153 was 97. 6%. The levels of CA125,CA199 and CA153 were correlated with prognosis by follow up study. Conclusion Detection of serum CA125,CA199 and combination with detection of CA153 may increase the sensitivity for the diagnosis of ovarian carcinoma, and be valuable in monitoring postoperative disease conditions.